Identical sales declined 0.8% year-over-year, while digital sales grew 13% and pharmacy remained strong. Adjusted EBITDA and net income fell, prompting a lowered fiscal 2026 outlook and accelerated operational changes. ACI Edge realignment and increased capital returns were announced.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.